Accelerating research

and development of

new antibiotics and


Antimicrobial Resistance

Antimicrobial resistance is a global threat for public health. As a result of an overuse of antibiotics, a growing number of bacteria is becoming insensitive to antibiotic treatment. Therefore, diseases that are currently easy to treat, such as lung or bladder infections, could once more become life-threatening.

The resistance to antibiotics is a growing concern in today’s society. The Organisation for Economic Cooperation and Development estimates that world-wide about 700,000 people die each year due to infections caused by drug-resistant bacteria. Since 1987, no new classes of antibiotics have been introduced onto the market. Additional research into new antibiotics, combinatorials, or alternative and preventive treatments, such as vaccines and probiotics, is important in the efforts to combat resistant bacteria.

The development of new drugs involves a great deal of time and research, and comes at a high cost. The return on investment for the development of new antibiotics is low, as these drugs are only used for a short period of time. After years of antibiotic development, the low-hanging fruits have been picked, and it is getting increasingly difficult to find novel compounds. Society urgently calls for major breakthroughs to identify, synthesize and produce new, better antibiotics and alternatives to successfully tackle antimicrobial resistance.

By matching partners for new public-private partnerships, NADP aims to accelerate the development pipeline to fill it with new antibiotics and new in prevention and care, to combat antimicrobial resistance.

Antimicrobial Resistance